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forBACKGROUND Evidence from large, randomized, controlled peripheral artery disease trials reporting long-term out-
comes using drug-coated balloons (DCBs) is limited. Previously, the DCB showed favorable 1-year outcomes compared
with conventional percutaneous transluminal angioplasty (PTA), yet durability of the treatment effect with DCBs remains
unknown.
OBJECTIVES This study sought to investigate the longer-term outcomes of a paclitaxel-eluting DCB compared to PTA
for femoropopliteal lesions.
METHODS We enrolled 331 patients with symptomatic (Rutherford 2 to 4) femoropopliteal lesions up to 18 cm in
length. Patients were randomly assigned in a 2:1 ratio to treatment with DCB or PTA. The 24-month assessments included
primary patency, freedom from clinically driven target lesion revascularization (CD-TLR), major adverse events, and
quality of life and functional outcomes as assessed by the EuroQOL-5D quality-of-life questionnaire, walking impairment
questionnaire, and 6-min walk test.
RESULTS At 24 months, patients treated with DCB showed signiﬁcantly higher primary patency when compared with
PTA (78.9% vs. 50.1%; p < 0.001). The rates of CD-TLR were 9.1% and 28.3% (p < 0.001) for the DCB and PTA groups,
respectively. The overall mortality rate in the DCB group was 8.1% versus 0.9% in the PTA group (p ¼ 0.008). There
were no device- or procedure-related deaths and no major amputations in either group through 24-month follow-up. The
rate of vessel thrombosis was low (1.5% DCB vs. 3.8% PTA; p ¼ 0.243), with no new events reported between 1 and 2
years. Both groups showed similar functional improvement at 2 years, although DCB patients achieved this level of
function with 58% fewer reinterventions.
CONCLUSIONS The 24-month outcomes from the trial demonstrate a durable and superior treatment effect of DCB versus
PTA with signiﬁcantly higher primary patency, lower CD-TLR, and similar functional status improvement with fewer repeat
interventions. (Randomized Trial of IN.PACT Admiral Drug Eluting Balloon vs Standard PTA for the Treatment of SFA and
Proximal Popliteal Arterial Disease [INPACT SFA I]; NCT01175850; and IN.PACT Admiral Drug-Coated Balloon vs. Standard
BalloonAngioplasty for theTreatmentofSuperﬁcialFemoralArtery [SFA] andProximalPoplitealArtery [PPA] [INPACTSFA II];
NCT01566461) (J Am Coll Cardiol 2015;66:2329–38) © 2015 by the American College of Cardiology Foundation.m the *UC Davis, Sacramento, California; yKaiser Permanente–Moanalua Medical Center and Clinic, Honolulu, Hawaii;
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2330E ndovascular procedures have becomethe predominant method for revascu-larization of patients with symptom-
atic peripheral artery disease (PAD), largely
due to their less invasive nature and low
complication rates (1). Although well estab-
lished, percutaneous transluminal angio-
plasty (PTA) of the superﬁcial femoral (SFA)
and popliteal arteries is associated with a
high incidence of restenosis when used for
anything but the most focal, noncomplex le-
sions (2). Self-expanding nitinol stents have
improved the durability of endovascular in-
terventions in the femoropopliteal segment.
Recent studies have reported superior re-
sults of stents over PTA for short tointermediate-length lesions in the SFA, with 1-year
patency rates ranging from 63% to 83% (3–6) and
longer-term patency rates of 60% to 75% (7,8).
Despite the beneﬁts of stents, concerns exist
regarding the effect of in-stent restenosis, stent frac-
tures, and other stent-related complications that
negatively affect the patient’s clinical progress over
the long term (9–11). The search, therefore, continues
for an effective and durable treatment strategy that
minimizes the need for permanent metal implants
and preserves future therapeutic options.SEE PAGE 2339Paclitaxel-eluting drug-coated balloons (DCBs)
have shown promise for the treatment of PAD (12–17).
Paclitaxel is a proven antiproliferative agent that is
well suited for this application due to its lipophilic
nature. When combined with an excipient (carrier)
molecule, paclitaxel is delivered into the vessel wall
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received August 25, 2015; revised manuscript received Septembpaclitaxel remain at the treatment site for up to 180
days with certain excipients (18). Single-center ex-
periences and small randomized trials have demon-
strated a reduction in restenosis rates and the need
for repeat procedures with DCB compared with stan-
dard PTA (12–15). More recently, larger prospective
multicenter trials comparing DCB and PTA have been
reported (17,19). The IN.PACT SFA randomized trial
evaluated the safety and effectiveness of the DCB
(IN.PACT Admiral, Medtronic, Santa Rosa, California)
compared with standard PTA for the treatment of
patients with symptomatic femoropopliteal artery
disease. The 1-year results from the IN.PACT SFA trial
demonstrated superior primary patency and a
reduction in clinically driven target lesion revascu-
larization (CD-TLR) with DCB compared with PTA
(19). More recently, a second paclitaxel-eluting DCB
has shown superior 1-year results in comparison to
PTA (17). Despite these favorable short-term results,
there are limited data regarding the longer-term
effectiveness of this novel approach for the treat-
ment of femoropopliteal disease. In the current
report, we describe the 2-year outcomes from the
IN.PACT SFA randomized trial.
METHODS
STUDY DESIGN. A detailed description of the
IN.PACT SFA trial design, inclusion and exclusion
criteria, and outcomes through 1 year have been
previously reported (19). The IN.PACT SFA trial is a
multicenter, randomized, single-blinded trial to
assess the safety and efﬁcacy of the DCB versus
standard PTA balloons in patients with symptomatic
SFA and/or proximal popliteal artery disease. Patients
were randomly assigned in a 2:1 ratio to treatmenton the scientiﬁc advisory boards without compen-
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2331with DCB (n ¼ 220) or PTA (n ¼ 111). Patients were
eligible for enrollment if they had moderate to severe
intermittent claudication or ischemic rest pain
(Rutherford 2 to 4), stenosis of 70% to 99% with
lesion lengths between 4 and 18 cm or occlusion with
lengths of #10 cm involving the superﬁcial femoral
and proximal popliteal arteries, and met all other
eligibility criteria, including successful pre-dilation.
Before enrollment, written informed consent was
obtained from all patients according to the protocols
approved by the institutional review board or ethics
committee at each investigational site. The trial was
conducted in accordance with the Declaration of
Helsinki, good clinical practice guidelines, and
applicable laws as speciﬁed by all relevant govern-
mental authorities.
The trial included independent oversight by a Data
Safety Monitoring Board and Clinical Events Com-
mittee (CEC) that reviewed and adjudicated all major
adverse events through 24 months post-intervention.
Independent duplex ultrasonography (VasCore, Mas-
sachusetts General Hospital, Boston, Massachusetts)
and angiography (SynvaCor, Springﬁeld, Illinois) core
laboratories analyzed procedural and follow-up im-
ages. The independent core laboratories and CEC will
remain blinded to the treatment assignments through
the 60-month follow-up duration.
ENDPOINT DEFINITIONS
Assessments through 24 months included: primary
patency, deﬁned as freedom from CD-TLR or
freedom from restenosis as determined by duplex
ultrasonography-derived peak systolic velocity ratio
#2.4; and CD-TLR, deﬁned as reintervention at the
target lesion due to symptoms or decrease in ankle-
brachial index (ABI) $20% or >0.15 when compared
with post-procedure baseline ABI. In addition, pri-
mary patency at 24 months plus the 30-day follow-
up window was analyzed. The primary composite
safety endpoint was freedom from device- and
procedure-related death through 30 days and freedom
from target limb major amputation and clinically
driven target vessel revascularization (CD-TVR)
through 24 months.
The major adverse event rate (death from any
cause, CD-TVR, major target limb amputation, and
thrombosis at target lesion site) was also evaluated at
24 months. Thrombosis was deﬁned as a total occlu-
sion due to thrombus formation, which is rapidly
evolving as conﬁrmed by sudden onset of symptoms
and documented by Duplex ultrasonography and/or
angiography. Additional endpoints evaluated through
24 months included cumulative binary restenosis(deﬁned as core laboratory–assessed restenosis by
Doppler ultrasound peak systolic velocity ratio >2.4 or
angiographic diameter stenosis $50% at 24 months or
before any revascularization), the individual compo-
nents of the major adverse event composite, and pri-
mary sustained clinical improvement (deﬁned as
freedom from target limb amputation, freedom from
target vessel revascularization, and increase in Ruth-
erford class at 24 months). Functional assessments
included general appraisal through administration of
the EuroQOL (EQ)-5D, a 5-dimension generic health
status questionnaire (20), and speciﬁc evaluation of
walking capacity using the Walking Impairment
Questionnaire (21). A 6-min walk test (22) was addi-
tionally conducted in the IN.PACT SFA II (U.S. patient
cohort).
STATISTICAL ANALYSIS. All analyses were on the
basis of the intent-to-treat principle. For baseline
characteristics, continuous variables were described
as mean  SD and were compared by Student t tests;
dichotomous and categorical variables were des-
cribed as counts and proportions and were compared
by the Fisher exact test or Cochran-Mantel-Haenszel
modiﬁed ridit scores, respectively. The Kaplan-
Meier method was used to evaluate time-to-event
data for primary patency and CD-TLR over the 24-
month follow-up period. The difference in the sur-
vival curves between groups was assessed using the
log-rank test. For other outcomes, in addition to the
descriptive statistics, the Fisher exact test was used
for binary outcomes and Student t test for continuous
outcomes. For all endpoints, the level of statistical
signiﬁcance was set at p < 0.05 with no correction for
multiple comparisons. Statistical analyses were per-
formed using SAS (SAS Institute, Cary, North Car-
olina) version 9.2 or higher.
RESULTS
The IN.PACT SFA trial included 331 patients ran-
domized to treatment with DCB (n ¼ 220) and PTA
(n ¼ 111). Through 24 months of follow-up, 17 DCB
subjects and 6 PTA subjects withdrew from the trial,
and 16 DCB subjects and 1 PTA subject died. Of the
remaining 187 DCB subjects eligible for the 24-month
evaluations, 170 (90.9%) had a completed 24-month
follow-up visit. Similarly, of the 104 PTA subjects
eligible for the 24-month evaluations, 94 (90.4%) had
a completed 24-month follow-up visit. As previously
reported, the treatment groups were well matched at
baseline with similar demographics, comorbidities,
and lesion characteristics (Table 1) (19). The mean
lesion length was 8.94  4.89 cm in the DCB group
versus 8.81  5.12 cm in the PTA group (p ¼ 0.815).
TABLE 1 Baseline Patient and Procedural Characteristics
IN.PACT
(n ¼ 220)
PTA
(n ¼ 111) p Value
Age, yrs 67.5  9.5 68.0  9.2 0.612
Male 65.0 (143/220) 67.6 (75/111) 0.713
Diabetes 40.5 (89/220) 48.6 (54/111) 0.161
Hypertension 91.4 (201/220) 88.3 (98/111) 0.431
Hyperlipidemia 84.5 (186/220) 82.0 (91/111) 0.637
Current smoker 38.6 (85/220) 36.0 (40/111) 0.719
ABI/TBI* 0.769  0.228 0.744  0.189 0.308
Rutherford clinical category 0.898
2 37.7 (83/220) 37.8 (42/111)
3 57.3 (126/220) 55.9 (62/111)
4 5.0 (11/220) 5.4 (6/111)
5 0.0 (0/220) 0.9 (1/111)
Lesion length, cm 8.94  4.89 8.81  5.12 0.815
Total occlusions 25.8 (57/221) 19.5 (22/113) 0.222
Severe calciﬁcation 8.1 (18/221) 6.2 (7/113) 0.662
Dissections 0.360
0 36.2 (80/221) 38.9 (44/113)
A–C 63.8 (141/221) 60.2 (68/113)
D–F 0.0 (0/221) 0.9 (1/113)
Provisional stenting 7.3 (16/220) 12.6 (14/111) 0.110
Values are mean SD or% (n/N). *TBI allowed/used in cases of incompressible vessels in phase II.
ABI ¼ ankle-brachial index; PTA ¼ percutaneous transluminal angioplasty; TBI ¼ toe-brachial
index.
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2332EFFECTIVENESS OUTCOMES THROUGH 24 MONTHS.
The primary patency rate through 24 months was
signiﬁcantly higher with DCB than PTA (78.9% vs.
50.1%; log rank p < 0.001) (Central Illustration). At the
end of the 30-day follow-up window for 2 years, the
primary patency rate was 73.5% for DCB versus 47.4%
for PTA. DCB-treated patients maintained signiﬁ-
cantly lower CD-TLR rates at 24 months compared
with patients treated with PTA (9.1% vs. 28.3%;
p < 0.001) (Table 2). Kaplan-Meier estimates of
freedom from CD-TLR are demonstrated in the Central
Illustration. Core laboratory–assessed cumulative bi-
nary restenosis rates by Kaplan-Meier estimate at 24
months were 19.8% for DCB versus 46.9% for PTA (log
rank p< 0.001). Signiﬁcantly higher primary sustained
clinical improvement was observed in the DCB group
compared with PTA (76.9% vs. 59.2%; p ¼ 0.003)
(Table 2). A post-hoc subgroup analysis showed a
beneﬁcial treatment effect of DCB across numerous
clinical and anatomic subgroups (Figure 1). Impor-
tantly, primary patency was signiﬁcantly better for
diabetic patients treated with DCB compared with PTA
(73.3% vs. 45.8%; p < 0.001). Female patients in the
DCB group outperformed their PTA-treated counter-
parts (Figure 1). Primary patency for female patients
treated with DCB was 76.7% compared with 42.3% for
those treated with PTA (p < 0.001).SAFETY OUTCOMES THROUGH 24 MONTHS. Table 3
summarizes the safety outcomes through the 24-month
follow-up. The primary safety composite endpoint of
freedom from 30-day device- and procedure-related
death and target limb major amputation and
CD-TVR within 24 months was 87.4% in the DCB
group versus 69.8% in the PTA group (p < 0.001).
Rates of CD-TVR remained signiﬁcantly lower for
patients treated with DCB versus PTA (12.6% vs.
30.2%; p < 0.001). Although there were no device- or
procedure-related deaths in either group, the rate of
all-cause mortality was higher for patients treated
with DCB compared with PTA (8.1% vs. 0.9%;
p ¼ 0.008). The causes of death as adjudicated by the
blinded, independent CEC are listed in Table 4. The
deaths occurred relatively late in the study follow-
up, with a median time to death of 564.5 days in
the DCB group and 397 days in the PTA group.
FUNCTIONAL OUTCOMES. At 24 months, both treat-
ment groups showed improvement from baseline in
all functional outcomes assessed, including the
quality-of-life assessment by the EQ-5D index, 6-min
walk test, and Walking Impairment Questionnaire
(Table 5). In the quality-of-life assessment using the
EQ-5D index, results trended in favor of patients
treated with DCB (Table 5). Using the 6-min walk test,
the distance covered at baseline was comparable be-
tween groups (253.2  123 m for DCB vs. 256.0 
114.7 m for PTA; p ¼ 0.883). At 24 months, there was
similar improvement in walking distance for the DCB
and PTA groups (30.9  87.7 m vs. 60.5  97.6 m;
p ¼ 0.117). Patients treated with DCB achieved these
similar levels of quality-of-life improvement despite
58% fewer reinterventions than with PTA.
DISCUSSION
The IN.PACT SFA randomized trial demonstrated
that, for lesions in the SFA and proximal popliteal
artery (mean length 8.9 cm), the DCB provided su-
perior outcomes at 1 year compared with standard
PTA (19). Primary patency and CD-TLR rates were
signiﬁcantly better in the DCB group. The 12-month
CD-TLR rate of 2.4% was the lowest reported in the
published medical data for a femoropopliteal endo-
vascular therapy. The current analysis of the longer-
term results from this trial demonstrates a sustained
beneﬁt of DCB over PTA at 24 months. The 24-month
DCB outcomes were excellent, with a primary patency
rate of 78.9% and a CD-TLR rate of only 9.1%. The
Kaplan-Meier curves for primary patency and CD-TLR
remain parallel after 1 year for the 2 treatment groups,
demonstrating no “catch up” phenomenon with re-
gard to late target lesion failure and the need for
CENTRAL ILLUSTRATION Durability of Treatment Effect Using a DCB for Femoropopliteal Lesions at 24 Months:
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(A) Primary patency by Kaplan-Meier estimate was signiﬁcantly higher in the drug-coated balloon (DCB) group than in the percutaneous
transluminal angioplasty (PTA) group (p < 0.001). The primary patency rate was 78.9% for DCB versus 50.1% for PTA at 24 months. Bars
represent 95% conﬁdence interval. All target lesion revascularization events were adjudicated by the independent and blinded clinical events
committee, and all ultrasound and angiographic images were analyzed by independent and blinded core laboratories. (B) Freedom from
clinically driven target lesion revascularization (CD-TLR) by Kaplan-Meier estimate was signiﬁcantly higher in the DCB group than in the PTA
group (p < 0.001). The CD-TLR rate was 91.0% for DCB versus 72.2% for PTA at 24 months. Bars represent 95% conﬁdence interval. All
target lesion revascularization events were adjudicated by the independent and blinded clinical events committee.
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TABLE 2 Effectiveness Outcomes at 24 Months
IN.PACT
(n ¼ 220)
PTA
(n ¼ 111) p Value*
Primary patency† 78.9 (42) 50.1 (54) <0.001‡
CD-TLR§ 9.1 (18/198) 28.3 (30/106) <0.001
Time to ﬁrst CD-TLR, days 351.9  165.9 261.7  139.0 0.049
All TLRk 10.1 (20/198) 29.2 (31/106) <0.001
Primary sustained clinical
improvement¶
76.9 (133/173) 59.2 (61/103) 0.003
ABI/TBI# 0.924  0.261 0.938  0.184 0.611
Values are % (n), % (n/N), or mean  SD. *Unless otherwise indicated, all tests were for supe-
riority using the Fisher exact test for binary variables and Student t test for continuous variables.
†Freedom from clinically driven TLR or freedom from restenosis as determined by Duplex ultra-
sound peak systolic velocity ratio #2.4 within 24 months. The 24-month primary patency was
calculated based on Kaplan-Meier estimate, and the number of primary patency failure subjects
are displayed in the parentheses. ‡Log rank p value. §Any reintervention at the target lesion due
to symptoms or drop of ABI of$20% or >0.15 when compared with post-procedure baseline ABI/
TBI. kIncludes clinically driven and incidental or duplex-driven TLR. ¶Freedom from target limb
amputation, TVR, and increase in Rutherford class. #TBI allowed/used in case of incompressible
vessels in phase II.
CD-TLR ¼ clinically driven target lesion revascularization; TLR ¼ target lesion revascularization;
TVR ¼ target vessel revascularization; other abbreviations as in Table 1.
FIGURE 1 Subgroup Analysis of Primary Patency at 24 Months
Subgroup IN.PACT
DCB %
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PTA %
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Forest plots show primary patency based on Kaplan-Meier estimate in key subgroup
and percutaneous transluminal angioplasty (PTA) for all subgroup analyses were statis
Classiﬁcation 4 subgroup. Treatment-by-subgroup interactions were tested using a C
treatment (DCB and PTA), subgroup, and the treatment-by-subgroup interaction. CI
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2334repeat interventions (Central Illustration). These
results support the notion that a short duration of
paclitaxel uptake into the vessel wall after balloon
angioplasty can result in effective inhibition of neo-
intimal proliferation and sustained clinical beneﬁt. At
2 years, these data continue to support an excellent
safety proﬁle with no major amputations in the DCB
group and no new thrombosis events reported
between 1 and 2 years.
Although no large randomized trials have been
published comparing DCB with bare-metal stents,
drug-eluting stents, or atherectomy, the IN.PACT
Admiral DCB results compare favorably with results
from other randomized clinical trials in this patient
population. Despite inclusion of longer lesion lengths
that are at a higher risk of treatment failure, the 2-
year primary patency rate of 78.9% is in line with
results from bare-metal and drug-eluting stent trials
(8,23–25). The 2-year CD-TLR rate of 9.1% remains 1 ofHazard Ratio [95% CI] p–value for
interaction
N.PACT DCB
10 15 20 25
3.25 [2.17, 4.87]
4.51 [2.40, 8.48]
2.48 [1.42, 4.34]
4.12 [0.75, 22.69]
NA
0.292
0.673
0.175
0.551
0.571
0.911
2.82 [1.61, 4.96]
3.49 [1.95, 6.24]
5.47 [2.24, 13.33]
2.78 [1.75, 4.40]
3.85 [1.26, 11.78]
2.65 [1.34, 5.21]
3.63 [1.97, 6.69]
3.97 [1.77, 8.88]
3.06 [1.92, 4.89]
3.35 [1.75, 6.41]
3.22 [1.92, 5.40]
s at 24 months. Comparisons between drug-coated balloon (DCB)
tically signiﬁcant at a signiﬁcance level of 0.05, except the Rutherford
ox proportional hazards model containing the main effects of
¼ conﬁdence interval; ITT ¼ intent-to-treat.
TABLE 4 Causes of Death* Through 24 Months
Treatment
Assignment
Days to
Death
Procedure-Related
(Y/N)
Device-Related
(Y/N)
Infarction of the right cerebral
hemisphere in the anterior
and medial ﬂow region
DCB 127 No No
Biliary sepsis DCB 168 No No
Sudden death DCB 287 No No
Perforated transverse colon
secondary to cecal volvulus
DCB 314 No No
Sepsis DCB 374 No No
Acute diastolic congestive heart
failure
DCB 540 No No
Metastatic colon cancer PTA 397 No No
Unknown DCB 541 No No
GI cancer DCB 561 No No
Cardiac arrest DCB 568 No No
Deterioration of general condition DCB 603 No No
Cardiac arrest DCB 610 No No
CAD DCB 615 No No
Acute respiratory failure DCB 657 No No
Dementia DCB 679 No No
Hypoxic respiratory failure DCB 681 No No
Ischemic cardiomyopathy DCB 699 No No
*Causes of death as reported by sites. Adjudicated by the blinded clinical events committee for relatedness to
device or procedure.
CAD ¼ coronary artery disease; GI ¼ gastrointestinal; other abbreviations as in Table 1.
TABLE 3 Safety Outcomes at 24 Months
IN.PACT
(n ¼ 220)
PTA
(n ¼ 111) p Value*
Primary safety composite† 87.4% (173/198) 69.8% (74/106) <0.001
Major adverse events‡ 19.2% (38/198) 31.1% (33/106) 0.023
All-cause death§ 8.1% (16/198) 0.9% (1/106) 0.008
Device- and procedure-related death 0.0% (0/198) 0.0% (0/106) >0.999
Clinically driven TVR 12.6% (25/198) 30.2% (32/106) <0.001
Target limb major amputation 0.0% (0/198) 0.0% (0/106) >0.999
Thrombosis 1.5% (3/198) 3.8% (4/106) 0.243
Values are % (n/N). *p values are based on Fisher exact test for superiority with signiﬁcance level of 0.05.
†Freedom from 30-day device- and procedure-related death and target limb major amputation and clinically
driven TVR within 24 months. ‡Composite of death, clinically-driven TVR, target limb major amputation, and
thrombosis. §No deaths were adjudicated as device- or procedure-related by the clinical events committee.
Median post-index days to death: 564.5 days in DCB versus 397 days in PTA.
PTA ¼ percutaneous transluminal angioplasty; other abbreviations as in Tables 1 and 2.
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2335the lowest ever reported for an SFA device trial. These
results were achieved despite a low rate of bailout
stenting (7.3%) in the DCB arm of the trial (19). This
low bailout stenting rate highlights the fact that
careful attention to technique and long-duration
balloon inﬂations can achieve satisfactory angio-
graphic results and obviate the need for stenting in
the majority of cases. The potential beneﬁts of
avoiding implantation of a permanent metallic
endoprosthesis in the femoropopliteal vascular bed
have been well described and include prevention of
complications associated with stent fracture and in-
stent restenosis (9). Once diffuse in-stent restenosis
or in-stent occlusion occurs, additional interventions
are associated with a high rate of recurrent restenosis
or reocclusion (26,27).
A post-hoc subgroup analysis demonstrated out-
comes in favor of DCB across a variety of clinical and
anatomic subgroups. With the exception of patients
having ischemic rest pain (Rutherford Category 4), all
subgroups showed better results with DCB. Longer
and more complex lesions, including total occlusions,
had signiﬁcantly better primary patency following
treatment with DCB. A strong treatment effect was
also observed for diabetic patients and women. These
ﬁndings are of great importance given the historically
poorer outcomes for diabetic patients following lower
extremity interventions (28,29).
One unexpected ﬁnding of the trial was a higher
mortality rate at 24 months in the DCB group.
Following evaluation by the independent, blinded
clinical events committee, however, none of the
deaths were deemed related to the study device or
the procedure. When compared with other published
series in a similar patient population, the 24-month
mortality rate in the PTA group in IN.PACT SFA
(0.9%) was unusually low. Typical mortality rates in
these trials range from 3.5% to 11% (7,15). However,
the mortality rate of 8.1% for DCB at 2 years is
consistent with results from contemporary PAD trials
(ranging from 7.6% to 9.0% [7,17]) and is in line with a
recent publication by Mueller et al. (30) in which they
observed higher mortality rates in PAD patients
compared with non-PAD control subjects. The higher
mortality rate in the DCB arm bears watching, how-
ever, and longer-term follow-up from the IN.PACT
SFA trial and results from other trials will provide
additional insights regarding this observation.
The ultimate goal of any lower extremity revascu-
larization procedure for patients with intermittent
claudication is to improve functional status, reduce
disability, and improve overall quality of life. In the
IN.PACT SFA trial, quality of life and walking
improvement, as assessed by the EQ-5D and walkingimpairment questionnaire at 2-year follow-up, was
similarly improved from baseline for patients under-
going PTA and DCB, despite 58% fewer re-
interventions for the DCB group. A similar result
was observed in the 2-year ABI/toe-brachial index
endpoint. This is the ﬁrst prospective, multicenter
randomized trial of peripheral artery devices in which
a subset of patients underwent serial 6-min walk
tests. There was similar improvement in walking
distance for both treatment groups. The maintenance
of this important patient-centered metric over 2
years is encouraging and reinforces a role of this
TABLE 5 24-Month Functional Outcomes
Outcomes
IN.PACT DCB PTA
p ValueBaseline 24 Months Baseline 24 Months
Quality-of-life assessment by EQ-5D index 0.7431  0.1652 (216) 0.8436  0.1862 (170) 0.7450  0.1627 (108) 0.7939  0.2107 (94)
Change from baseline by EQ-5D index — 0.0957  0.2159 (167) — 0.0545  0.2286 (92) 0.151
6-min walking test, m* 253.2  123.0 (119) 298.0  124.3 (73) 256.0  114.7 (60) 311.6  137.0 (35)
Change in walking distance from baseline by 6MWT, m* — 30.9  87.7 (72) — 60.5  97.6 (35) 0.117
Walking Impairment Questionnaire scores, %
Walking impairment 42.1  28.9 (214) 72.5  34.1 (170) 41.3  29.9 (109) 67.2  33.6 (93) 0.228†
Walking distance 32.3  27.7 (177) 68.1  38.8 (106) 30.4  24.2 (83) 58.6  41.7 (53) 0.156†
Walking speed 31.8  23.5 (177) 54.6  34.6 (106) 29.3  17.1 (82) 47.7  31.6 (52) 0.231†
Stair climbing 42.5  31.3 (175) 67.5  36.4 (106) 40.7  29.0 (83) 56.6  38.3 (52) 0.082†
Values are mean  SD (n). The number of subjects evaluated at each interval is displayed in the parentheses. *Data collected in phase II only. †p values for 24-month assessments.
6MWT ¼ 6-min walk test; EQ ¼ EuroQOL; other abbreviations as in Table 1.
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claudication. The IN.PACT SFA trial and previous
interventional trials have not been designed to truly
prove the beneﬁt of newer endovascular therapies
over standard therapies with regard to walking dis-
tance and quality of life. Any trial that evaluates
walking impairment or quality of life at a prescribed
time, while allowing reintervention for target lesion
failure in the interval time period (and failing to
quantify the decrement in quality of life associated
with additional procedures), might be expected to
fail to capture the full clinical beneﬁt of a therapy
that results in improved vessel patency. In the
future, innovative trial designs should address this
shortcoming.
Although the DCB was shown to be superior to PTA
in this trial, these results may not be generalizable to
other DCBs. Each DCB is unique with respect to the
paclitaxel dose (varying from 2 to 3.5 mg/mm2), the
excipient molecule, the balloon material, and the
balloon and coating technology used. Each of these
features can inﬂuence the dose of paclitaxel delivered
into the vessel wall and the ultimate effectiveness of
the DCB for the prevention of neointimal proliferation
(31,32). Although the results of the IN.PACT SFA trial
and other randomized trials demonstrate superiority
of DCB over PTA for short to intermediate-length le-
sions, the beneﬁt of DCB has not been proven for
longer lesions (>18 cm) and more complex lesion
subsets, including severely calciﬁed lesions and
thrombus-containing lesions. Ongoing, prospective,
multicenter registries, including the IN.PACT Global
Study, are evaluating the effectiveness of DCB for
these challenging lesions.
STUDY LIMITATIONS. As previously reported, the
IN.PACT SFA trial was deliberately and prospectively
conducted in 2 sequential phases, and the results ofphase I were not released until the completion of
phase II. When the data were analyzed, there were
no statistical differences between the 2 phases.
Although the patient, study sponsor, and independent
angiographic and ultrasound laboratories were blin-
ded to the treatment received, signiﬁcant differences
in the appearance of the DCB compared with a stan-
dard angioplasty balloon prevented blinding of the
treating physician. In addition, the physician respon-
sible for clinical follow-up of the research subjects was
also not blinded to the treatment received and was
aware of the ultrasound and/or angiographic results at
the follow-up visits to ensure appropriate clinical
decision making. All repeat revascularization pro-
cedures in both arms of the trial were reviewed by the
blinded CEC as to their appropriateness.
CONCLUSIONS
The 2-year outcomes from this prospective, multi-
center, multinational, randomized trial demonstrate
durability and continued superiority of the IN.PACT
Admiral DCB over PTA. DCB use resulted in signiﬁ-
cantly higher primary patency and a marked reduction
in the need for repeat interventions compared with
PTA. These results demonstrate sustained clinical
beneﬁt of local delivery of paclitaxel and have the po-
tential to change the treatment paradigm for patients
with symptomatic femoropopliteal artery disease.
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Endo-
vascular procedures have become an accepted method of
revascularization for patients with intermittent claudica-
tion that have failed medical therapy and a walking
program.
COMPETENCY IN PATIENT CARE AND
PROCEDURAL SKILLS: Patients with complex femo-
ropopliteal lesions should be made aware that restenosis
rates following balloon angioplasty are high, and alter-
native therapies such as DCBs may provide better patency
and reduce the need for repeat procedures.
TRANSLATIONAL OUTLOOK 1: The 24-month results
from the IN.PACT SFA trial demonstrate a sustained
treatment effect from the local delivery of the antiproli-
ferative agent paclitaxel at the time of balloon
angioplasty.
TRANSLATIONAL OUTLOOK 2: Although DCBs pro-
vide better outcomes than standard balloon angioplasty,
randomized comparisons of DCB angioplasty with other
treatment modalities such as atherectomy and bare-
metal or drug-eluting stents are needed.
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